NASDAQ:KYNB
Kyntra Bio, Inc.
Kyntra Bio, Inc.'s revenue fell 78.3% in fiscal 2025 to $6.4M while operating margin fell to −712.7%, its lowest in 10 years. Free cash flow was −$4.8M, −74.7% of revenue, and the diluted share count rose 1.0%.Summary generated from Kyntra Bio, Inc.'s SEC filings. Latest annual report filed Mar 16, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$6.4M
Revenue growth−78.3%
Revenue, 5-yr CAGR−48.4%
Gross margin91.4%
Operating margin−712.7%
Net margin2848.6%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$4.8M
FCF margin−74.7%
Share count change+1.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 235 | 141 | 47 | 30 | 6 |
| Operating income | −289 | −301 | −323 | −150 | −46 |
| Net income | −290 | −294 | −284 | −48 | 183 |
| Free cash flow | −87 | −150 | −318 | −138 | −5 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 8-KNotice of delisting or listing-rule failure
Oct 6, 2026 - 8-KDirector or officer change
Oct 1, 2026 - 4Insider transaction report
Sep 9, 2026 - 8-KEntry into a material agreement
Aug 31, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 16, 2026